The estimated Net Worth of Michael S Weiss is at least $43.5 Million dollars as of 14 November 2023. Mr. Weiss owns over 147,058 units of TG Therapeutics Inc stock worth over $26,081,096 and over the last 12 years he sold TGTX stock worth over $4,745,096. In addition, he makes $12,674,700 as Executive Chairman of the Board, President, and Chief Executive Officer at TG Therapeutics Inc.
Michael has made over 8 trades of the TG Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 147,058 units of TGTX stock worth $249,999 on 14 November 2023.
The largest trade he's ever made was buying 1,197,604 units of TG Therapeutics Inc stock on 10 February 2023 worth over $1,005,987. On average, Michael trades about 38,670 units every 82 days since 2012. As of 14 November 2023 he still owns at least 1,130,520 units of TG Therapeutics Inc stock.
You can see the complete history of Mr. Weiss stock trades at the bottom of the page.
Michael S. Weiss serves as Executive Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Weiss is also currently a director of the Company. From 2002 to 2009, Mr. Weiss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc., where he helped the company acquire and develop its lead drug, Auryxia®, as well as executed a strategic alliance for Auryxia with Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd. worth more than $100 million. Mr. Weiss began his professional career as a lawyer with Cravath, Swaine & Moore LLP. He earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. Based on Mr. Weiss’s biotechnology and pharmaceutical industry experience, as well as his extensive management experience, the Board of Directors believes that Mr. Weiss has the appropriate set of skills to serve as a member of the Board. Mr. Weiss also serves as a director and Executive Vice Chairman, Strategic Development of Fortress Biotech, Inc., as Chairman of the Board of Directors and Executive Chairman of Mustang Bio, Inc., and as Chairman of the Board of Directors of Checkpoint Therapeutics, Inc. Additionally, Mr. Weiss co-founded and served as Co-Portfolio Manager and Managing Partner of Opus Point Partners, LLC from 2009 to 2019.
As the Executive Chairman of the Board, President, and Chief Executive Officer of TG Therapeutics Inc, the total compensation of Michael Weiss at TG Therapeutics Inc is $12,674,700. There are no executives at TG Therapeutics Inc getting paid more.
Michael Weiss is 54, he's been the Executive Chairman of the Board, President, and Chief Executive Officer of TG Therapeutics Inc since 2011. There are 5 older and 4 younger executives at TG Therapeutics Inc. The oldest executive at TG Therapeutics Inc is William Kennedy, 75, who is the Independent Director.
Over the last 12 years, insiders at TG Therapeutics Inc have traded over $23,556,837 worth of TG Therapeutics Inc stock and bought 549,710 units worth $3,334,566 . The most active insiders traders include Capital Management, L.P.Kol..., Michael S Weiss, and Sean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of $1,103,023. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth $432,822.
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
TG Therapeutics Inc executives and other stock owners filed with the SEC include: